Literature DB >> 9341717

Early detection of irreversibly damaged ischemic tissue by flumazenil positron emission tomography in cats.

W D Heiss1, R Graf, T Fujita, K Ohta, B Bauer, J Löttgen, K Wienhard.   

Abstract

BACKGROUND AND
PURPOSE: Ligands for cerebral benzodiazepine receptors were used in the past to indicate the intactness of cortical neurons in subacute to chronic states after stroke and thus to differentiate among brain regions with complete or incomplete infarction and with functional deactivation. For planning acute interventional therapy, however, a marker of irreversible damage in early ischemia is needed. We studied the applicability of [11C]flumazenil (FMZ) for differentiation between tissue with and without potential of recovery in the first hours after focal experimental ischemia.
METHODS: In 11 cats, cerebral blood flow, cerebral metabolic rate for oxygen, oxygen extraction fraction, and FMZ binding were studied repeatedly by positron emission tomography before, during, and up to 12 hours after transient middle cerebral artery occlusion (MCAO) (30 minutes in 2, 60 minutes in 7, and 120 minutes in 2 cats, respectively). Development of the defects in energy metabolism were compared with the defects in FMZ binding (2 to 3 hours and 8 to 9 hours after MCAO), with the pattern of disturbed glucose metabolism (determined 12 hours after MCAO), and with the size of the infarcts (determined approximately 15 hours after MCAO).
RESULTS: Irrespective of the level of reperfusion, defects in FMZ binding (2 to 3 hours after MCAO) were closely related to areas with severely depressed oxygen consumption and predicted the size of the final infarcts, whereas preserved FMZ binding indicated intact cortex. Depression of glucose metabolism was in all animals larger than the defects in FMZ binding and the infarcts, indicating functional deactivation of brain areas beyond the permanent morphological damage. In addition, FMZ distribution within 2 minutes after injection was significantly correlated to flow and yielded reliable perfusion images.
CONCLUSIONS: The reduction of FMZ binding early after focal ischemia reflects irreversible neuronal damage that otherwise only can be detected by multitracer studies. Our experimental data and first clinical applications suggest that FMZ has potential as an indicator of developing infarction. Since FMZ distribution additionally images perfusion, this tracer might be useful for the selection of patients who would benefit from acute therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9341717     DOI: 10.1161/01.str.28.10.2045

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  13 in total

Review 1.  Imaging the physiological evolution of the ischemic penumbra in acute ischemic stroke.

Authors:  Richard Leigh; Linda Knutsson; Jinyuan Zhou; Peter Cm van Zijl
Journal:  J Cereb Blood Flow Metab       Date:  2017-03-27       Impact factor: 6.200

Review 2.  Inflammation in CNS neurodegenerative diseases.

Authors:  Jodie Stephenson; Erik Nutma; Paul van der Valk; Sandra Amor
Journal:  Immunology       Date:  2018-04-17       Impact factor: 7.397

3.  Recovered neuronal viability revealed by Iodine-123-iomazenil SPECT following traumatic brain injury.

Authors:  Hiroyasu Koizumi; Hirosuke Fujisawa; Tetsu Kurokawa; Eiichi Suehiro; Hideyuki Iwanaga; Jyoji Nakagawara; Michiyasu Suzuki
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-04       Impact factor: 6.200

4.  Early-stage 11C-Flumazenil PET predicts day-14 selective neuronal loss in a rodent model of transient focal cerebral ischemia.

Authors:  Jessica L Hughes; John S Beech; P Simon Jones; Dechao Wang; David K Menon; Franklin I Aigbirhio; Tim D Fryer; Jean-Claude Baron
Journal:  J Cereb Blood Flow Metab       Date:  2019-10-22       Impact factor: 6.200

5.  PET in Cerebrovascular Disease.

Authors:  William J Powers; Allyson R Zazulia
Journal:  PET Clin       Date:  2010-01-01

6.  Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice.

Authors:  Michael T Heneka; Mutiah Ramanathan; Andreas H Jacobs; Lucia Dumitrescu-Ozimek; Andras Bilkei-Gorzo; Thomas Debeir; Magdalena Sastre; Norbert Galldiks; Andreas Zimmer; Mathias Hoehn; Wolf-Dieter Heiss; Thomas Klockgether; Matthias Staufenbiel
Journal:  J Neurosci       Date:  2006-02-01       Impact factor: 6.167

7.  Defining the ischemic penumbra using hyperacute neuroimaging: deriving quantitative ischemic thresholds.

Authors:  Andria L Ford; Hongyu An; Katie D Vo; Weili Lin; Jin-Moo Lee
Journal:  Transl Stroke Res       Date:  2012-05-01       Impact factor: 6.829

8.  11C-flumazenil positron emission tomography demonstrates reduction of both global and local cerebral benzodiazepine receptor binding in a patient with Stiff Person Syndrome.

Authors:  Norbert Galldiks; Alexander Thiel; Cathleen Haense; Gereon R Fink; Rüdiger Hilker
Journal:  J Neurol       Date:  2008-06-27       Impact factor: 4.849

9.  Assessing neuronal density in peri-infarct cortex with PET: Effects of cortical topology and partial volume correction.

Authors:  Thomas Funck; Mohammed Al-Kuwaiti; Claude Lepage; Peter Zepper; Jeffrey Minuk; Hyman M Schipper; Alan C Evans; Alexander Thiel
Journal:  Hum Brain Mapp       Date:  2016-09-10       Impact factor: 5.038

10.  Characterisation of [123I]iomazenil distribution in a rat model of focal cerebral ischaemia in relation to histopathological findings.

Authors:  Tomohito Kaji; Yuji Kuge; Chiaki Yokota; Masafumi Tagaya; Hiroyasu Inoue; Tohru Shiga; Kazuo Minematsu; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-08       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.